Page last updated: 2024-11-13

cyslabdan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cyslabdan: potentiates imipenem activity against methicillin-resistant S. aureus; isolated from Streptomyces; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24778014
CHEMBL ID4070880
MeSH IDM0521940

Synonyms (5)

Synonym
cyslabdan
CHEMBL4070880
956507-17-8
(2r)-3-[[(1r,2s,3s,4as,8as)-2,3-dihydroxy-5,5,8a-trimethyl-1-[(2e)-3-methylpenta-2,4-dienyl]-3,4,4a,6,7,8-hexahydro-1h-naphthalen-2-yl]methylsulfanyl]-2-acetamidopropanoic acid
AKOS040748205
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1449632Potentiation of imipenem-induced antibacterial activity against methicillin-reisitant Staphylococcus aureus assessed as imipenem MIC (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, May-05, Volume: 131Recent updates of carbapenem antibiotics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's7 (77.78)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]